Glaxo S.p.a.

Glaxo Wellcome Spa

Glaxo Group Limited

Glaxosmithkline LLC

Boehringer Ingelheim Gmbh

Isf S.p.a.

Giovanni Gaviraghi

Claudio Semeraro

Dino Micheli

Daniele Pieraccioli

Alan D Borthwick

Alfredo Cugola

Tino Rossi

Daniele Andreotti

Alcide Perboni

Stefano Biondi

Daniele Donati

Emiliangelo Ratti

Claudio Bismara

Allan D Borthwick

Bruno Tamburini

Mario Pinza

Fabrizio Micheli

Giorgio Pifferi

Luca Tarsi

Antonella Ursini

Giovanna Tedesco

Giorgio Tarzia

David Gordon Trist

Luciano Dorigotti

Aldo Feriani

Domenica Antonia Pizzi

Gabriella Finizia

Roberto Carlesso

Angelo Mario Reggiani

Mauro Quartaroli

Simone Giacobbe

Francesco Crespi

A compound of formula (I), salts and metabolically labile esters thereof, wherein R represents optionally substituted aryl or heteroaryl group; A represents a propylene chain or A is a chain of members one of which is selected from an oxygen or sulphur atom or the group NH or a substituted derivative thereof and the other two members are methylene groups, having antibacterial activity, processes for their preparation and to their use in medicine.

Tricyclic carbapenem compounds

The use of CCK-B antagonists for the treatment of sleep disorders.

Use of cck-b receptor antagonists for the treatment of sleep disorders

A composition comprising diethyl (E)-4-[2-[(tert-butyloxycarbonyl)vinyl]phenyl-1,4-dihydro-2,6-dimethylpyri dine-3,5-dicarboxylate (lacidipine) and 4'-[[2-n-propyl-4-methyl-6 -(1-methylbenziimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2 -carboxylic acid (telmisartan) or a physiologically functional derivative thereof.

Medicaments for the treatment of hypertension

Indole derivatives

A compound of the formula 1-cyclohexyloxycarbonyloxethyl (4S, 8S, 9R 10S, 12R)-4-methoxy-10-(1-hydroxyethyl)-11-oxo-1-azatricyclo[7.2.0.0..sup.3,8 ]undec-2-ene-2-carboxylate which is useful as a pharmaceutical composition to treat bacterial infection.

10(1-hydroxyethyl)-11-oxo-1-azatricyclo/7.2.0.0..sup.3.8/

The invention relates to the compound of formula (I) ##STR1## wherein A represents an unsubstituted ethenyl group in the trans (E) configuration or a physiologically acceptable salt or metabilically labile ester thereof which are antagonists of excitatory amino acids, to processes for their preparation and to their use in medicine.

Lacidipine for the treatment of arteriosclerosis

The invention relates to heterocyclic derivatives having antibacterial activity, to processes for their preparation, to compositions containing them, and to their medicinal uses. The derivatives according to the invention have the following general formula: ##STR1##

Derivatives of 1-azatricyclo[7.2.03,8]undec-2-ene-2-carboxyclic acid

The invention relates to compounds of formula (I). ##STR1## or a salt, or metabolically labile ester thereof wherein R represents a group selected from halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, hydroxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, SO.sub.2 R.sub.1 or COR.sub.1 wherein R.sub.1 represents hydroxy, methoxy, or amino; m is zero or an integer 1 or 2;

Indole derivatives and pharmaceutical use thereof

The invention relates to compounds of formula I. ##STR1## or a salt, or metabolically labile ester thereof wherein A represents an unsubstituted ethenyl, group in the trans configuration, R.sub.1 represents a substituted phenyl group which are antagonists of excitatory amino acids, to processes for their preparation and to their use in medicine.

Compounds are described of the formula: ##STR1## and physiologically acceptable salts thereof, in which R.sub.1 -R.sub.7 are defined hereinafter. The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion concentration and thus may be useful for the treatment of cardiovascular disorders such as hypertension.

Heterocyclic compounds and their preparation and pharmaceutical

Compounds of the general formula (I) ##STR1## in which: R.sub.1 represents a hydroxyl protecting group; and

4-(2-Oxo-cyclohexyl) azetidinones

Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group;

Heterocyclic compounds and their pharmaceutical formulation

Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group:

Heterocyclic 1,4 dihydropyridine derivatives

Growing community of inventors

Verona, Italy

Giovanni Gaviraghi